Page last updated: 2024-11-01

ondansetron and Cardiovascular Diseases

ondansetron has been researched along with Cardiovascular Diseases in 1 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"The purpose of this article is to outline the risk of cardiac adverse events (AEs) from 5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron and palonosetron."2.505-Hydroxytryptamine3 receptor antagonists and cardiac side effects. ( Brygger, L; Herrstedt, J, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brygger, L1
Herrstedt, J1

Reviews

1 review available for ondansetron and Cardiovascular Diseases

ArticleYear
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:10

    Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinoline

2014